Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | RFA AR 19 007

Opportunity Information: Apply for RFA AR 19 007

Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) is a National Institutes of Health (NIH) funding opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) designed to support short, time-sensitive mechanistic studies that can be added onto clinical projects that are already underway. The core idea is to take advantage of the fact that many ongoing clinical trials and observational studies are already enrolling well-characterized participants and collecting valuable clinical data and biospecimens. Instead of starting a brand-new standalone project, this announcement funds an "ancillary" study that rides alongside an existing parent clinical project to answer focused mechanistic questions that are tightly aligned with the NIAMS mission, such as understanding disease biology in arthritis, musculoskeletal conditions, and skin diseases, or related organ systems and pathways within NIAMS scientific priorities.

The parent clinical project can be either an interventional clinical trial or a non-interventional clinical study (for example, an observational cohort) as long as it is actively collecting patient samples and/or clinical data that the ancillary project can use. A strong parent project is expected to provide the essential foundation: a defined cohort of participants, established infrastructure for recruitment and follow-up, existing study operations, and access to clinical information and biological samples. The ancillary study is meant to leverage these resources so that the proposed mechanistic work is feasible within a short time window, cost-efficient, and capable of producing meaningful biological insight without duplicating the substantial effort and expense already invested in building the cohort and collecting data.

The emphasis on "mechanistic" research means the funded work should go beyond descriptive clinical outcomes and aim to explain how a disease process works at a biological level. In practice, that could include studies that examine immune pathways, tissue or cellular phenotypes, molecular signatures, biomarker discovery and validation, or other approaches that clarify disease mechanisms using samples or data from the parent project. NIAMS frames this as a way to enhance the scientific value of the parent study, broaden what can be learned from existing participants and specimens, and ultimately accelerate progress toward better diagnosis, treatment, and prevention by identifying new targets or mechanistic hypotheses that can be pursued in future work.

This opportunity uses the NIH R21 mechanism, which is generally intended for exploratory, developmental projects that can produce high-impact insights with a limited scope and budget. The listing includes an award ceiling of $250,000, signaling that projects should be focused, efficient, and tightly tied to the parent study's resources. A notable feature of this FOA is that it offers an accelerated review and award process, reinforcing the point that these studies are time-sensitive and often need to be initiated quickly to align with enrollment milestones, sample collection schedules, or other operational timelines of the ongoing parent clinical project.

The announcement explicitly states "Clinical Trial Not Allowed," meaning the application itself cannot propose a new clinical trial as the ancillary study. The parent project may be a clinical trial, but the funded ancillary work must not introduce a new interventional clinical trial under this award. Instead, it should function as mechanistic research conducted in conjunction with the ongoing project, typically using collected specimens, additional assays, or analyses that do not constitute launching a new trial.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education when specified); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

At the same time, there are important restrictions around foreign participation. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply as the applicant organization. However, "foreign components" as defined by the NIH Grants Policy Statement are allowed, which typically means a U.S. applicant can include certain foreign activities or collaborations if they meet NIH policy requirements and are justified scientifically.

Administrative details in the provided source data indicate this is a discretionary grant opportunity under the health category, with CFDA number 93.846, and it was issued by NIH under Funding Opportunity Number RFA-AR-19-007. The original closing date listed is April 2, 2019, and the record creation date is April 4, 2018. The overall purpose remains clear regardless of those dates: to create a fast, flexible funding path for adding high-value, mechanistic science onto existing clinical projects so the biomedical community can extract more knowledge from cohorts, data systems, and biospecimens that are already in place.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2018-04-04.
• Applicants must submit their applications by 2019-04-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $250,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AR 19 007

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: